News

Traditional antibody-drug conjugates (ADCs) have delivered cytotoxic payloads—often tubulin or topoisomerase inhibitors—directly to antigen-positive tumor cells, providing targeted cell killing while limiting off-target effects. However, the emergence of degrader–antibody conjugates (DACs), particularly those based on proteolysis-targeting chimeras (PROTACs) and molecular glues, has introduced a new therapeutic strategy: harnessing targeted protein degradation rather than inhibition.

Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion

Piramal Pharma Solutions (PPS) has announced the launch of a state-of-the-art payload-linker development and manufacturing suite at its Riverview, Michigan, drug-substance facility. This new...

Lonza, a global leader in contract development and manufacturing, has announced an exclusive single-target licensing agreement with Bristol Myers Squibb (BMS) for its proprietary SYNtecan™ linker-payload platform*. This agreement marks a significant milestone in advancing next-generation antibody-drug conjugate (ADC) therapeutics for oncology and other serious diseases.

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

The field of antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates (bsADCs) is rapidly expanding, offering new hope for the treatment of a range of solid tumors with high unmet medical need. Recent abstracts from the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA, highlight several promising technological and therapeutic advances with Biocytogen’s RenLite® transgenic mouse platform and proprietary linker/payload technologies at the forefront.

NEOK002 (previously known as ABL209) is a novel, bispecific ADC designed to simultaneously target two key cancer antigens—Epidermal Growth Factor Receptor (EGFR), a key oncogenic driver in multiple tumor types, and Mucin-1 (MUC1), a tumor-associated antigen characterized by aberrant glycosylation and overexpression.

Pfizer has discontinued development of its early-stage immune-stimulating antibody conjugate (ISAC) PF-08046037, an investigational therapy targeting PD-L1, as part of a strategic realignment of its oncology pipeline. The decision, described as being for 'strategic business reasons' and not due to safety or efficacy concerns, comes after a series of notable clinical successes and high-profile deals that have reshaped Pfizer’s approach to cancer drug development.

AbbVie Announces $1.4 Billion Manufacturing Campus in North Carolina: Largest Single-Site Investment in Company History

Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.